Get the Stockscreener App
0.9811
0.11%
0.0011
Achilles Therapeutics Plc Adr stock is traded at $0.9811, with a volume of 123.02K.
It is up +0.11% in the last 24 hours and down -8.31% over the past month.
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
See More
Previous Close:
$0.98
Open:
$0.99
24h Volume:
123.02K
Relative Volume:
0.18
Market Cap:
$40.31M
Revenue:
-
Net Income/Loss:
$-66.88M
P/E Ratio:
-0.5451
EPS:
-1.8
Net Cash Flow:
$-62.91M
1W Performance:
-0.89%
1M Performance:
-8.31%
6M Performance:
+15.17%
1Y Performance:
+18.20%
1-Day Range:
$0.9601
$0.99
1-Week Range:
$0.922
$1.0098
52-Week Range:
$0.63
$1.76
Achilles Therapeutics Plc Adr Stock (ACHL) Company Profile
Name
Achilles Therapeutics Plc Adr
Sector
Industry
Phone
-
Address
-
Compare ACHL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHL
Achilles Therapeutics Plc Adr
|
0.9811 | 40.31M | 0 | -66.88M | -62.91M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Achilles Therapeutics Plc Adr Stock (ACHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | Chardan Capital Markets | Buy |
| Apr-26-21 | Initiated | JP Morgan | Underweight |
| Apr-26-21 | Initiated | Oppenheimer | Outperform |
| Apr-26-21 | Initiated | Piper Sandler | Overweight |
View All
Achilles Therapeutics Plc Adr Stock (ACHL) Latest News
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market - GlobeNewswire Inc.
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
ACHL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Check Out Achilles Therapeutics Plc ADR (ACHL)’s Trade Data Rather Than the Analysts’ Views - SETE News
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
why Achilles Therapeutics Plc ADR [ACHL] is a Good Choice for Investors After New Price Target of $1.25 - The DBT News
What Analysts Were Expecting After PowerFleet Inc (NASDAQ: AIOT) rose 2.40% - Stocks Register
Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter
Achilles Therapeutics ends TIL-based cancer therapy trials - Investing.com
You Should Read This Analysis Before Investing in Achilles Therapeutics Plc ADR (NASDAQ:ACHL) - US Post News
Achilles stock climbs on strategic focus (NASDAQ:ACHL) - Seeking Alpha
Achilles Therapeutics Announces Strategic Update - Yahoo Finance
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why - Yahoo New Zealand News
Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why - Yahoo Sport Australia
Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study - Yahoo Lifestyle UK
Achilles Therapeutics Announces Research Collaboration with - GlobeNewswire
Achilles Therapeutics faces Nasdaq delisting over share price - Investing.com
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference - GlobeNewswire
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights - GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis - Yahoo Finance
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation - Quantisnow
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock - Yahoo Finance
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why - Nasdaq
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 - Yahoo Finance
Novo (NVO) Posts Positive Data From Diabetes Study on CagriSema - Nasdaq
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board - GlobeNewswire
Achilles Therapeutics PlcADR Shares Close the Day 10.1% HigherDaily Wrap - Nasdaq
Achilles Therapeutics Announces Pricing of Initial Public Offering - GlobeNewswire
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Achilles Therapeutics Plc Adr Stock (ACHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):